Skip to content

house · Committee report

H. Rept. 118-959

TREAT AND REDUCE OBESITY ACT OF 2024

2024-12-27

Committees

Associated legislation

Text

Background

H.R. 4818 was introduced on July 20, 2023, and was referred to the Committee on Ways and Means and the Committee on Energy and Commerce. Committee Hearings The Committee on Ways and Means held the following hearing(s) concerning the policy in H.R. 4818: On May 10, 2023, the Committee on Ways and Means Health Subcommittee held a hearing titled, Examining Policies that Inhibit Innovation and Patient Access to probe policies limiting the number of innovative treatments and cures that reach patients. The hearing explored Medicare's prohibition of Part D plans covering anti-obesity medications.

Committee Action

The Committee on Ways and Means marked up H.R. 4818, the Treat and Reduce Obesity Act of 2023, on June 27, 2024, and favorably reported the bill, as amended, to the House of Representatives (with quorum being present). D. Designated Hearing Pursuant to clause 3(c)(6) of rule XIII, the following hearing was used to develop and consider H.R. 4818: ``Examining Policies that Inhibit Innovation and Patient Access.'' May 10, 2023 II. EXPLANATION OF THE BILL A. Reasons for Change The Committee on Ways and Means' reason for change is to update Medicare Part D policy to ensure seniors aging into Medicare can continue treatment on anti-obesity medications they have taken previously. Additionally, the committee wants to ensure Medicare's coverage of intensive behavioral therapy reflects current guidelines for the treatment of obesity. B. Explanation of Provisions Section 1. Short Title The short title is ``Treat and Reduce Obesity Act of 2024''. Section 2. Including Weight Loss Agents as Covered Part D Drugs Under the Medicare Program in Certain Circumstances Provides Medicare Part D coverage of anti-obesity medications (AOMs) to individuals aging into Medicare who are currently being treated by an AOM, ensuring they do not lose coverage for their effective therapies. Section 3. Reviewing Coverage for Intensive Behavioral Therapy for Obesity Under the Medicare Program Requires Medicare to re-evaluate its coverage of Intensive Behavioral Therapy (IBT) so that seniors can be effectively treated through diet and exercise. C. Effective Date The bill would become effective January 1, 2027. III. VOTES OF THE COMMITTEE In compliance with the Rules of the House of Representatives, the following statement is made concerning the vote of the Committee on Ways and Means during the markup consideration of H.R. 4818, the ``Treat and Reduce Obesity Act of 2023,'' on June 27, 2024. The vote on the amendment offered by Mr. Doggett to the amendment in the nature of a substitute to H.R. 4818, which would require CMS to negotiate the price of drugs receiving Medicare coverage under this legislation was not agreed to by a roll call vote of 17 yeas to 23 nays (with a quorum being present). The vote was as follows: ---------------------------------------------------------------------------------------------------------------- Representative Yea Nay Present Representative Yea Nay Present ---------------------------------------------------------------------------------------------------------------- Mr. Smith (MO)..................... ...... X ......... Mr. Neal............. X ...... ......... Mr. Buchanan....................... ...... X ......... Mr. Doggett.......... X ...... ......... Mr. Smith (NE)..................... ...... X ......... Mr. Thompson......... X ...... ......... Mr. Kelly.......................... ...... X ......... Mr. Larson........... X ...... ......... Mr. Schweikert..................... ...... X ......... Mr. Blumenauer....... X ...... ......... Mr. LaHood......................... ...... X ......... Mr. Pascrell......... X ...... ......... Dr. Wenstrup....................... ...... X ......... Mr. Davis............ X ...... ......... Mr. Arrington...................... ...... ...... ......... Ms. Sanchez.......... X ...... ......... Dr. Ferguson....................... ...... X ......... Ms. Sewell........... X ...... ......... Mr. Estes.......................... ...... X ......... Ms. DelBene.......... X ...... ......... Mr. Smucker........................ ...... X ......... Ms. Chu.............. X ...... ......... Mr. Hern........................... ...... X ......... Ms. Moore............ X ...... ......... Ms. Miller......................... ...... X ......... Mr. Kildee........... X ...... ......... Dr. Murphy......................... ...... ...... ......... Mr. Beyer............ X ...... ......... Mr. Kustoff........................ ...... X ......... Mr. Evans............ ...... ...... ......... Mr. Fitzpatrick.................... ...... X ......... Mr. Schneider........ X ...... ......... Mr. Steube......................... ...... ...... ......... Mr. Panetta.......... X ...... ......... Ms. Tenney......................... ...... X ......... Mr. Gomez............ X ...... ......... Mrs. Fischbach..................... ...... X ......... Mr. Moore.......................... ...... X ......... Mrs. Steel......................... ...... X ......... Ms. Van Duyne...................... ...... X ......... Mr. Feenstra....................... ...... X ......... Ms. Malliotakis.................... ...... X ......... Mr. Carey.......................... ...... X ......... ---------------------------------------------------------------------------------------------------------------- In compliance with the Rules of the House of Representatives, the following statement is made concerning the vote of the Committee on Ways and Means during the markup consideration of H.R. 4818, the ``Treat and Reduce Obesity Act of 2023,'' on June 27, 2024. The vote on the amendment offered by Mr. Schneider to the amendment in the nature of a substitute to H.R. 4818, which would remove restrictions on Part D coverage of anti-obesity medications, returning Part D coverage for anti-obesity medications back to the original coverage provided in H.R. 4818 was not agreed to by a roll call vote of 15 yeas to 22 nays to 1 present (with a quorum being present). The vote was as follows: ---------------------------------------------------------------------------------------------------------------- Representative Yea Nay Present Representative Yea Nay Present ---------------------------------------------------------------------------------------------------------------- Mr. Smith (MO)..................... ...... X ......... Mr. Neal............. X ...... ......... Mr. Buchanan....................... ...... X ......... Mr. Doggett.......... ...... ...... X Mr. Smith (NE)..................... ...... X ......... Mr. Thompson......... X ...... ......... Mr. Kelly.......................... ...... X ......... Mr. Larson........... X ...... ......... Mr. Schweikert..................... ...... X ......... Mr. Blumenauer....... X ...... ......... Mr. LaHood......................... ...... X ......... Mr. Pascrell......... X ...... ......... Dr. Wenstrup....................... ...... X ......... Mr. Davis............ X ...... ......... Mr. Arrington...................... ...... ...... ......... Ms. Sanchez.......... X ...... ......... Dr. Ferguson....................... ...... X ......... Ms. Sewell........... X ...... ......... Mr. Estes.......................... ...... X ......... Ms. DelBene.......... X ...... ......... Mr. Smucker........................ ...... X ......... Ms. Chu.............. X ...... ......... Mr. Hern........................... ...... X ......... Ms. Moore............ X ...... ......... Ms. Miller......................... ...... X ......... Mr. Kildee........... X ...... ......... Dr. Murphy......................... ...... ...... ......... Mr. Beyer............ X ...... ......... Mr. Kustoff........................ ...... X ......... Mr. Evans............ ...... ...... ......... Mr. Fitzpatrick.................... ...... X ......... Mr. Schneider........ X ...... ......... Mr. Steube......................... ...... ...... ......... Mr. Panetta.......... X ...... ......... Ms. Tenney......................... ...... X ......... Mr. Gomez............ X ...... ......... Mrs. Fischbach..................... ...... X ......... Mr. Moore.......................... ...... X ......... Mrs. Steel......................... ...... X ......... Ms. Van Duyne...................... ...... X ......... Mr. Feenstra....................... ...... X ......... Ms. Malliotakis.................... ...... X ......... Mr. Carey.......................... ...... X ......... ---------------------------------------------------------------------------------------------------------------- In compliance with the Rules of the House of Representatives, the following statement is made concerning the vote of the Committee on Ways and Means during the markup consideration of H.R. 4818, the ``Treat and Reduce Obesity Act of 2023,'' on June 27, 2024. The vote on the amendment offered by Mr. Beyer to the amendment in the nature of a substitute to H.R. 4818, which would add a study on impacts of GLP-1s on gut health was not agreed to by a roll call vote of 17 yeas to 21 nays (with a quorum being present). The vote was as follows: ---------------------------------------------------------------------------------------------------------------- Representative Yea Nay Present Representative Yea Nay Present ---------------------------------------------------------------------------------------------------------------- Mr. Smith (MO)..................... ...... X ......... Mr. Neal............. X ...... ......... Mr. Buchanan....................... ...... X ......... Mr. Doggett.......... X ...... ......... Mr. Smith (NE)..................... ...... X ......... Mr. Thompson......... X ...... ......... Mr. Kelly.......................... ...... X ......... Mr. Larson........... X ...... ......... Mr. Schweikert..................... ...... X ......... Mr. Blumenauer....... X ...... ......... Mr. LaHood......................... ...... X ......... Mr. Pascrell......... X ...... ......... Dr. Wenstrup....................... ...... X ......... Mr. Davis............ X ...... ......... Mr. Arrington...................... ...... ...... ......... Ms. Sanchez.......... X ...... ......... Dr. Ferguson....................... ...... X ......... Ms. Sewell........... X ...... ......... Mr. Estes.......................... ...... X ......... Ms. DelBene.......... X ...... ......... Mr. Smucker........................ ...... X ......... Ms. Chu.............. X ...... ......... Mr. Hern........................... ...... X ......... Ms. Moore............ X ...... ......... Ms. Miller......................... ...... ...... ......... Mr. Kildee........... X ...... ......... Dr. Murphy......................... ...... ...... ......... Mr. Beyer............ X ...... ......... Mr. Kustoff........................ ...... X ......... Mr. Evans............ ...... ...... ......... Mr. Fitzpatrick.................... ...... X ......... Mr. Schneider........ X ...... ......... Mr. Steube......................... ...... ...... ......... Mr. Panetta......... X ...... ......... Ms. Tenney......................... ...... X ......... Mr. Gomez............ X ...... ......... Mrs. Fischbach..................... ...... X ......... ..................... ...... ...... ......... Mr. Moore.......................... ...... X ......... ..................... ...... ...... ......... Mrs. Steel......................... ...... X ......... ..................... ...... ...... ......... Ms. Van Duyne...................... ...... X ......... ..................... ...... ...... ......... Mr. Feenstra....................... ...... X ......... ..................... ...... ...... ......... Ms. Malliotakis.................... ...... X ......... ..................... ...... ...... ......... Mr. Carey.......................... ...... X ......... ..................... ...... ...... ......... ---------------------------------------------------------------------------------------------------------------- In compliance with the Rules of the House of Representatives, the following statement is made concerning the vote of the Committee on Ways and Means during the markup consideration of H.R. 4818, the ``Treat and Reduce Obesity Act of 2023,'' on June 27, 2024. H.R. 4818 was ordered favorably reported to the House of Representatives as amended by a roll call vote of 36 yeas to 4 nays (with a quorum being present). The vote was as follows: ---------------------------------------------------------------------------------------------------------------- Representative Yea Nay Present Representative Yea Nay Present ---------------------------------------------------------------------------------------------------------------- Mr. Smith (MO)..................... X ...... ......... Mr. Neal............. ...... X ......... Mr. Buchanan....................... X ...... ......... Mr. Doggett.......... ...... X ......... Mr. Smith (NE)..................... X ...... ......... Mr. Thompson......... X ...... ......... Mr. Kelly.......................... X ...... ......... Mr. Larson........... X ...... ......... Mr. Schweikert..................... X ...... ......... Mr. Blumenauer....... X ...... ......... Mr. LaHood......................... X ...... ......... Mr. Pascrell......... X ...... ......... Dr. Wenstrup....................... X ...... ......... Mr. Davis............ X ...... ......... Mr. Arrington...................... X ...... ......... Ms. Sanchez.......... ...... X ......... Dr. Ferguson....................... X ...... ......... Ms. Sewell........... X ...... ......... Mr. Estes.......................... X ...... ......... Ms. DelBene.......... X ...... ......... Mr. Smucker........................ X ...... ......... Ms. Chu.............. X ...... ......... Mr. Hern........................... X ...... ......... Ms. Moore............ X ...... ......... Ms. Miller......................... X ...... ......... Mr. Kildee........... X ...... ......... Dr. Murphy......................... ...... ...... ......... Mr. Beyer............ X ...... ......... Mr. Kustoff........................ X ...... ......... Mr. Evans............ ...... ...... ......... Mr. Fitzpatrick.................... X ...... ......... Mr. Schneider........ ...... X ......... Mr. Steube......................... ...... ...... ......... Mr. Panetta......... X ...... ......... Ms. Tenney......................... X ...... ......... Mr. Gomez............ X ...... ......... Mrs. Fischbach..................... X ...... ......... ..................... ...... ...... ......... Mr. Moore.......................... X ...... ......... ..................... ...... ...... ......... Mrs. Steel......................... X ...... ......... ..................... ...... ...... ......... Ms. Van Duyne...................... X ...... ......... ..................... ...... ...... ......... Mr. Feenstra....................... X ...... ......... ..................... ...... ...... ......... Ms. Malliotakis.................... X ...... ......... ..................... ...... ...... ......... Mr. Carey.......................... X ...... ......... ..................... ...... ...... ......... ---------------------------------------------------------------------------------------------------------------- IV. BUDGET EFFECTS OF THE BILL A. Committee Estimate of Budgetary Effects With respect to clause 3(d) of rule XIII of the Rules of the House of Representatives, a cost estimate provided by the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not made available to the Committee in time for the filing of this report. B. Statement Regarding New Budget Authority and Tax Expenditures Budget Authority In compliance with clause 3(c)(2) of rule XIII of the Rules of the House of Representatives, the Committee states that the bill involved no new or increased budget authority. The Committee states further that the bill involves no new or increased tax expenditures. C. Cost Estimate Prepared by the Congressional Budget Office With respect to the requirements of clause 3(c)(2) of rule XIII of the Rules of the House of Representatives and section 308(a) of the Congressional Budget Act of 1974 and with respect to requirements of clause (3)(c)(3) of rule XIII of the Rules of the House of Representatives and section 402 of the Congressional Budget Act of 1974, the Committee has requested but not received a cost estimate for this bill from the Director of Congressional Budget Office. The Chairman of the Committee shall cause such estimate and statement to be printed in the Congressional Record upon its receipt by the Committee. V. OTHER MATTERS TO BE DISCUSSED UNDER THE RULES OF THE HOUSE A. Committee Oversight Findings and Recommendations With respect to clause 3(c)(1) of rule XIII of the Rules of the House of Representatives, the Committee made findings and recommendations that are reflected in this report. B. Statement of General Performance Goals and Objectives With respect to clause 3(c)(4) of rule XIII of the Rules of the House of Representatives, the Committee advises that the bill does not authority funding, so no statement of general performance goals and objectives is required. C. Information Relating to Unfunded Mandates This information is provided in accordance with section 423 of the Unfunded Mandates Reform Act of 1995 (Pub. L. No. 104- 4). The Committee has determined that the bill does not contain Federal mandates on the private sector. The Committee has determined that the bill does not impose a Federal intergovernmental mandate on State, local, or tribal governments. D. Congressional Earmarks, Limited Tax Benefits, and Limited Tariff Benefits With respect to clause 9 of rule XXI of the Rules of the House of Representatives, the Committee has carefully reviewed the provisions of the bill, and states that the provisions of the bill do not contain any congressional earmarks, limited tax benefits, or limited tariff benefits within the meaning of the rule. E. Duplication of Federal Programs In compliance with clause 3(c)(5) of rule XIII of the Rules of the House of Representatives, the Committee states that no provision of the bill establishes or reauthorizes: (1) a program of the Federal Government known to be duplicative of another Federal program; (2) a program included in any report

Source: https://api.congress.gov/v3/committee-report/118/hrpt/959